[HTML][HTML] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot… - Molecular cancer, 2023 - Springer
Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …
[HTML][HTML] Angiogenic signaling pathways and anti-angiogenic therapy for cancer
ZL Liu, HH Chen, LL Zheng, LP Sun… - Signal transduction and …, 2023 - nature.com
Angiogenesis, the formation of new blood vessels, is a complex and dynamic process
regulated by various pro-and anti-angiogenic molecules, which plays a crucial role in tumor …
regulated by various pro-and anti-angiogenic molecules, which plays a crucial role in tumor …
[HTML][HTML] The impact of VEGF on cancer metastasis and systemic disease
Metastasis is the leading cause of cancer-associated mortality and the underlying
mechanisms of cancer metastasis remain elusive. Both blood and lymphatic vasculatures …
mechanisms of cancer metastasis remain elusive. Both blood and lymphatic vasculatures …
[HTML][HTML] Comprehensive review of targeted therapy for colorectal cancer
YH Xie, YX Chen, JY Fang - Signal transduction and targeted therapy, 2020 - nature.com
Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …
[HTML][HTML] Tumor-associated neutrophils and neutrophil-targeted cancer therapies
H Que, Q Fu, T Lan, X Tian, X Wei - … et Biophysica Acta (BBA)-Reviews on …, 2022 - Elsevier
Neutrophils are the frontline cells in response to microbial infections and are involved in a
range of inflammatory disorders in the body. In recent years, neutrophils have gained …
range of inflammatory disorders in the body. In recent years, neutrophils have gained …
[HTML][HTML] VEGF/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment
Non-small cell lung cancer (NSCLC) is the leading cause of death by cancer worldwide.
Despite developments in therapeutic approaches for the past few decades, the 5-year …
Despite developments in therapeutic approaches for the past few decades, the 5-year …
[HTML][HTML] Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments
X Wei, Y Chen, X Jiang, M Peng, Y Liu, Y Mo, D Ren… - Molecular cancer, 2021 - Springer
Background Vasculogenic mimicry (VM) is a recently discovered angiogenetic process
found in many malignant tumors, and is different from the traditional angiogenetic process …
found in many malignant tumors, and is different from the traditional angiogenetic process …
Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy
CX Dominguez, S Müller, S Keerthivasan, H Koeppen… - Cancer discovery, 2020 - AACR
With only a fraction of patients responding to cancer immunotherapy, a better understanding
of the entire tumor microenvironment is needed. Using single-cell transcriptomics, we chart …
of the entire tumor microenvironment is needed. Using single-cell transcriptomics, we chart …
Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer
In tumorous tissues, the absence of vasculature supportive tissues intimates the formation of
leaky vessels and pores (100 nm to 2 μm in diameter) and the poor lymphatic system offers …
leaky vessels and pores (100 nm to 2 μm in diameter) and the poor lymphatic system offers …
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
D Fukumura, J Kloepper, Z Amoozgar… - Nature reviews Clinical …, 2018 - nature.com
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …
however, the majority of patients with cancer do not derive benefit from these treatments …